3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
24
Magnetic Resonance Spectroscopy
10
Carboplatin
8
Nivolumab
7
Docetaxel
7
Paclitaxel
6
Gemcitabine
6
Trastuzumab
5
Taxes
5
Injections
5
Fluorouracil
5
Fluorodeoxyglucose F18
5
Drug Therapy
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
X-Rays
4
Specimen Handling
4
Radiotherapy
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Leucovorin
4
durvalumab
3
atezolizumab
3
Surveys and Questionnaires
3
Standard of Care
3
Irinotecan
3
Immunohistochemistry
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
rucaparib
×
Thoracic
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts